Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Lantheus Medical Imaging reports Phase 1 data of LMI 1195 heart failure PET imaging agent

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced Phase 1 data for its novel heart failure Positron Emission Tomography (PET) imaging agent, LMI 1195, which is in development for the evaluation of patients at risk of heart failure or sudden cardiac death.

9 Jun 2010

Preoperative BB usage to help prevent POMI revealed at Vascular Annual Meeting

A regional quality improvement effort aimed at increasing the use of preoperative beta-blocker usage to help prevent postoperative myocardial infarction was revealed today at the 64th Vascular Annual Meeting presented by the Society for Vascular Surgery.

9 Jun 2010

4% of South Asian people carry mutated gene that causes heart failure

One in 25 people from India and other south Asian countries carries a mutated gene that causes heart failure.

9 Jun 2010

Phase 2 study results of Qnexa in patients with OSA presented at SLEEP 2010

VIVUS, Inc. today announced that data from a previously reported phase 2 study evaluating the safety and efficacy of the investigational drug Qnexa for the treatment of obstructive sleep apnea were presented at SLEEP 2010, the 24th Annual Meeting of the Associated Professional Sleep Societies.

8 Jun 2010

Medicare bidding program will lead to 'suicide bidding', says Pennsylvania Association of Medical Suppliers

Providers of home medical equipment and services across Pennsylvania are proposing a fiscally responsible alternative to the mislabeled "competitive" bidding scheme currently under way in Medicare that will actually discourage competition, reduce access to care for many of Pennsylvania's more than two million Medicare beneficiaries, and put hundreds of Pennsylvania's homecare providers out of business.

8 Jun 2010

GTx presents quality of life results from Ostarine Phase IIb study in cancer cachexia patients at ASCO 2010

GTx, Inc. today presented additional results from the Ostarine™ Phase IIb study demonstrating an improvement in quality of life (fatigue and anorexia) in cancer patients with muscle wasting (cancer cachexia) who demonstrated improvement in functional performance as measured by stair climb. Ostarine (GTx-024) is GTx's lead selective androgen receptor modulator (SARM) which the company is developing for the treatment of cancer cachexia.

8 Jun 2010

Community-based health promotion program reduces heart disease, stroke in seniors: Researcher

A community-based health promotion program delivered by over 500 peer volunteers significantly reduces heart disease and stroke in seniors, Canadian Stroke Network researcher Dr. Janusz Kaczorowski told the Canadian Stroke Congress today.

8 Jun 2010

Guardian Home Care Holdings, Cardiocom provide home telehealth technology to patients with chronic illnesses

Guardian Home Care Holdings, Inc., a leading provider of home care and hospice services, announced it has entered into a business relationship with Cardiocom to provide advanced home telehealth technology to patients with chronic illnesses. Cardiocom is a developer, manufacturer and clinical service provider of award-winning telehealth solutions.

7 Jun 2010

Clinical trial data of imetelstat in patients with breast cancer presented at ASCO annual meeting

Geron Corporation today announced the presentation of data from the clinical trial of imetelstat (GRN163L), the company's telomerase inhibitor drug, in combination with paclitaxel and bevacizumab in patients with breast cancer at the 2010 American Society of Clinical Oncology annual meeting in Chicago.

7 Jun 2010

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Millennium: The Takeda Oncology Company today reported on data from oral presentations of VELCADE® (bortezomib) for Injection based therapy in multiple myeloma presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). These data highlight VELCADE based therapy in both transplant and non-transplant eligible previously untreated multiple myeloma patients, as well as VELCADE used as induction and/or maintenance therapy.

7 Jun 2010

Research roundup: Evidence-based medicine consumer/expert divide; Pay for performance limitations; Improving community health centers

Health Affairs: Evidence That Consumers Are Skeptical About Evidence-Based Health Care - This survey of more than 1,500 patients with employer-based insurance found "there is a fundamental disconnect between the central tenets of evidence-based health care and the knowledge, values, and beliefs held by many consumers."

5 Jun 2010

Millennium announces data on VELCADE in treatment of patients with amyloidosis

Millennium: The Takeda Oncology Company today announced data examining the use of VELCADE in the treatment of patients with relapsed or refractory light chain (AL) amyloidosis. Amyloidosis is a rare condition in which excessive proteins build up in organs or tissues, such as the heart, kidney or liver. These data were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Illinois, June 4-8, 2010.

5 Jun 2010

Nile Therapeutics receives Nasdaq non-compliance notice

Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, today announced that, on June 1, 2010, the Company received a letter from The Nasdaq Stock Market indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, Nile was not in compliance with Marketplace Rule 5550(a)(2).

4 Jun 2010

SERCA2a gene therapy proves effective in people with advanced heart failure: Researchers

Researchers at Mount Sinai School of Medicine have developed a new gene therapy that is safe and effective in reversing advanced heart failure. SERCA2a (produced as MYDICAR-) is a gene therapy designed to stimulate production of an enzyme that enables the failing heart to pump more effectively.

4 Jun 2010

Rate of in-hospital mortality decreases and hospital readmission increases for heart failure patients: JAMA

An analysis of Medicare data from 1993 through 2006 for older patients hospitalized for heart failure indicates that along with a decrease in hospital length of stay, the rate of in-hospital and 30-day mortality has decreased, while the rate of hospital readmission and discharge to skilled nursing facilities has increased, according to a study in the June 2 issue of JAMA.

3 Jun 2010

Study: Shortened hospital stays may bring increased risks of return

"To save costs, hospitals for years have been discharging patients after shorter stays. But at the same time more people are having to return to hospital for additional care within a month of their initial treatment, according to a major new study of Medicare heart-failure patients."

3 Jun 2010

First Edition: June 2, 2010

In today's news, insurance regulators fail to meet an early deadline for setting standards on premium spending rules within the new health law.

2 Jun 2010

Heart attack patients treated beyond maximum recommended time have increased mortality: Study

An examination of the treatment received by patients with myocardial infarction (heart attack) at 80 hospitals in Quebec indicates that those who received either primary percutaneous coronary intervention (PPCI; such as angioplasty) or fibrinolysis (administration of medication to dissolve blood clots) beyond the times recommended in international guidelines had a significantly increased risk of death within 30 days, along with an increased risk of the combined outcome of death or readmission for heart attack or heart failure at one year, according to a study in the June 2 issue of JAMA.

2 Jun 2010

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

CoaguSense™, Inc., a diagnostic device company that has been in stealth mode for the past two years, today unveiled the first portable point-of-care Prothrombin Time/International Normalized Ratio (PT/INR) analyzer to directly detect blood clotting time for patients stabilized on oral anti-coagulation medications such as Coumadin® or warfarin.

2 Jun 2010

Targeted Genetics reports net income of $1.8M for fourth-quarter 2009 compared to net loss of $10.8M in 2008

Targeted Genetics Corporation today announced its financial results for the fourth quarter and full year ended December 31, 2009.

1 Jun 2010

Heart Failure News and Research

Further Reading

Lantheus Medical Imaging reports Phase 1 data of LMI 1195 heart failure PET imaging agent

Preoperative BB usage to help prevent POMI revealed at Vascular Annual Meeting

4% of South Asian people carry mutated gene that causes heart failure

Phase 2 study results of Qnexa in patients with OSA presented at SLEEP 2010

Medicare bidding program will lead to 'suicide bidding', says Pennsylvania Association of Medical Suppliers

GTx presents quality of life results from Ostarine Phase IIb study in cancer cachexia patients at ASCO 2010

Community-based health promotion program reduces heart disease, stroke in seniors: Researcher

Guardian Home Care Holdings, Cardiocom provide home telehealth technology to patients with chronic illnesses

Clinical trial data of imetelstat in patients with breast cancer presented at ASCO annual meeting

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Research roundup: Evidence-based medicine consumer/expert divide; Pay for performance limitations; Improving community health centers

Millennium announces data on VELCADE in treatment of patients with amyloidosis

Nile Therapeutics receives Nasdaq non-compliance notice

SERCA2a gene therapy proves effective in people with advanced heart failure: Researchers

Rate of in-hospital mortality decreases and hospital readmission increases for heart failure patients: JAMA

Study: Shortened hospital stays may bring increased risks of return

First Edition: June 2, 2010

Heart attack patients treated beyond maximum recommended time have increased mortality: Study

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

Targeted Genetics reports net income of $1.8M for fourth-quarter 2009 compared to net loss of $10.8M in 2008

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News